Voltage gated sodium channels (VGSC) underlie the electrical excitability of nerve and muscle. VGSCs consist of pore forming α-subunits and auxiliary β-subunits. There are ten cloned α-subunits and 4 β-subunits. The β-subunits modulate the localisation, expression and functional properties of α-subunits [
1]. Different α-subunits have distinct electrophysiological and pharmacological properties [
2]. The complex pattern of expression of α-subunits may imply special roles for particular subunits in different cell types [
3]. Many loss- as well as gain-of-function mutations of α-subunits have been identified in human conditions characterised with epilepsy, seizures, ataxia and increased sensitivity to pain. This suggests that mutations of VGSC in humans are significant factors in aetiology of neuronal diseases [
4].
Nociceptors are a subset of sensory neurons that respond to noxious thermal, mechanical and chemical stimuli. Nociceptors express multiple subtypes of α-subunits [
3]. Tissue and nerve damage leads to changes in expression and function of α-subunits that in turn can lead to change in the excitability of sensory neurons. Changes in the excitability of sensory neurons are thought to underlie some chronic pain conditions [
5,
6]. Na
v1.8 and Na
v1.7 are two α-subunits that are abundant in nociceptive sensory neurons [
3,
7,
8]. Na
v1.8 is expressed exclusively in sensory neurons and is not found in the CNS [
9]. Functional characterization of Na
v1.8 positive neurons revealed that more than 85% are nociceptors [
8]. Na
v1.7 is expressed principally in peripheral neurons with very weak expression detected in CNS [
10,
11]. As there are no subunit specific blockers, gene knockouts in mice have provided insights into the role of individual α-subunits genes in pain [
5]. Deletion of the Na
v1.8 gene [
12] and nociceptor-specific knockout of the Na
v1.7 [
13] gene have identified a role for these two α-subunits in setting mechanical and, to a lesser extent, thermal pain thresholds. In addition, behavioral studies have revealed deficits in inflammatory pain models, most dramatically in the nociceptor-specific Na
v1.7 knockout [
12,
13]. These findings suggest that these α-subunits could be targets for new anti-inflammatory drugs.
Peripheral nerve injury leads to lowered pain thresholds, enhanced responsiveness and/or ectopic activity in sensory neurons that ultimately leads to hyperalgesia and allodynia [
5,
6]. Changes in expression of α-subunits of VGSCs have been documented in models of peripheral nerve injury [
5,
6]. This has lead to the hypothesis that modulation of α-subunits in sensory neurons may underlie the increased neuronal excitability of sensory neurons following peripheral nerve injury. Pharmacological blockade of sodium channel activity has been shown to attenuate ectopic activity [
14,
15] and reverse hyperalgesia following nerve injury [
16]. While the role of Na
v1.7 in neuropathic pain remains to be investigated, analysis of a Na
v1.8 knockout mouse indicated that it is not involved in alteration of pain threshold following peripheral nerve injury [
17]. This is in contrast to the finding of Lai
et al who reported that antisense oligonucleotides directed against Na
v1.8 administered intrathecally completely reverse neuropathic pain behavior [
18]. It is possible that this discrepancy could be due to the up-regulation of the Na
v1.7 channel seen in the Na
v1.8 knockout mouse [
12] which might mask an otherwise important role for Na
v1.8 in neuropathic pain.
In the present study we investigated the role of the Nav1.7 channel in neuropathic pain using nociceptor-specific deletion of Nav1.7 in mouse. In addition, we readdressed the role of Nav1.8 in neuropathic pain by generating a double knockout of Nav1.8 and Nav1.7. We reasoned that the co-deletion of Nav1.7 in Nav1.8-expressing neurons should reveal any potential role for Nav1.8 in neuropathic pain.